Valeant sells iNova Pharmaceuticals for $930 Million
Baker McKenzie has acted for Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") in entering into an agreement to sell its iNova Pharmaceuticals (“iNova”) business to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group for $930 million in cash.